Management of patients with advanced non-small cell lung cancer: role of gefitinib

por Velcheti, Vamsidhar, Morgensztern, Daniel, Govindan, Ramaswamy
Publicado 2010

Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas

por Oronsky, Bryan, Ma, Patrick C., Morgensztern, Daniel, Carter, Corey A.
Publicado 2017

Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014

por Trikalinos, Nikolaos A., Tan, Benjamin R., Amin, Manik, Liu, Jingxia, Govindan, Ramaswamy, Morgensztern, Daniel
Publicado 2020

Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy

por Schenone, Aaron D, Luo, Jingqin, Montgomery, Luke, Morgensztern, Daniel, Adkins, Douglas R, Van Tine, Brian A
Publicado 2014

A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations

por Devarakonda, Siddhartha, Pellini, Bruna, Verghese, Luke, Park, Haeseong, Morgensztern, Daniel, Govindan, Ramaswamy, Suresh, Rama, Oppelt, Peter, Baggstrom, Maria Q., Wu, Ningying, Waqar, Saiama N.
Publicado 2021

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

por Langer, Corey J., Gajra, Ajeet, Gridelli, Cesare, Konduri, Kartik, Morgensztern, Daniel, Spigel, David, Talbot, Denis, Thomas, Michael, Weiss, Jared, Pilot, Richard, Bhore, Rafia, Wolfsteiner, Marianne, Ong, Teng Jin, Socinski, Mark
Publicado 2021

Exploring the Feasibility of Utilizing Limited Gene Panel Circulating Tumor DNA Clearance as a Biomarker in Patients With Locally Advanced Non-Small Cell Lung Cancer

por Knapp, Brendan, Mezquita, Laura, Devarakonda, Siddhartha, Aldea, Mihaela, Waqar, Saiama N., Pepin, Kym, Ward, Jeffrey P., Botticella, Angela, Howarth, Karen, Knape, Charlene, Morris, Clive, Govindan, Ramaswamy, Besse, Benjamin, Morgensztern, Daniel
Publicado 2022

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors

por Bagegni, Nusayba A., Park, Haeseong, Kraft, Katlyn, O-Toole, Maura, Gao, Feng, Waqar, Saiama N., Ratner, Lee, Morgensztern, Daniel, Devarakonda, Siddhartha, Amin, Manik, Baggstrom, Maria Q., Liang, Chris, Selvaggi, Giovanni, Wang-Gillam, Andrea
Publicado 2022

RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer

por Morgensztern, Daniel, Rose, Michal, Waqar, Saiama N., Morris, John, Ma, Patrick C., Reid, Thomas, Brzezniak, Christina E., Zeman, Karen G., Padmanabhan, Arvinda, Hirth, JoAnn, I. Spira, Alexander, Trepel, Jane B, Padda, Sukhmani K.
Publicado 2019

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

por Morgensztern, Daniel, Dols, Manuel Cobo, Ponce Aix, Santiago, Postmus, Pieter E., Bennouna, Jaafar, Fischer, Jürgen R., Juan-Vidal, Oscar, Stewart, David J., Ardizzoni, Andrea, Bhore, Rafia, Wolfsteiner, Marianne, Reck, Martin, Talbot, Denis, Govindan, Ramaswamy, Ong, Teng Jin
Publicado 2021

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy

por Thomas, Michael, Spigel, David R, Jotte, Robert M, McCleod, Michael, Socinski, Mark A, Page, Ray D, Gressot, Laurent, Knoble, Jeanna, Juan, Oscar, Morgensztern, Daniel, Isla, Dolores, Kim, Edward S, West, Howard, Ko, Amy, Ong, Teng Jin, Trunova, Nataliya, Gridelli, Cesare
Publicado 2017

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

por Camidge, D. Ross, Morgensztern, Daniel, Heist, Rebecca S., Barve, Minal, Vokes, Everett, Goldman, Jonathan W., Hong, David S., Bauer, Todd M., Strickler, John H., Angevin, Eric, Motwani, Monica, Parikh, Apurvasena, Sun, Zhaowen, Bach, Bruce Allen, Wu, Jun, Komarnitsky, Philip B., Kelly, Karen
Publicado 2021

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

por Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Spira, Alex, Angevin, Eric, Su, Wu-Chou, Hong, David S., Strickler, John H., Motwani, Monica, Dunbar, Martin, Parikh, Apurvasena, Noon, Elysa, Blot, Vincent, Wu, Jun, Kelly, Karen
Publicado 2023

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

por Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Angevin, Eric, Hong, David S., Rybkin, Igor I., Barve, Minal, Bauer, Todd M., Delmonte, Angelo, Dunbar, Martin, Motwani, Monica, Parikh, Apurvasena, Noon, Elysa, Wu, Jun, Blot, Vincent, Kelly, Karen
Publicado 2021

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

por Felip, Enriqueta, Moreno, Victor, Morgensztern, Daniel, Curigliano, Giuseppe, Rutkowski, Piotr, Trigo, José Manuel, Calvo, Aitana, Kowalski, Dariusz, Cortinovis, Diego, Plummer, Ruth, Maio, Michele, Ascierto, Paolo A., Vladimirov, Vladimir I., Cervantes, Andres, Zudaire, Enrique, Hazra, Anasuya, T’jollyn, Huybrecht, Bandyopadhyay, Nibedita, Greger, James G., Attiyeh, Edward, Xie, Hong, Calvo, Emiliano
Publicado 2022

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

por Owonikoko, Taofeek K., Park, Keunchil, Govindan, Ramaswamy, Ready, Neal, Reck, Martin, Peters, Solange, Dakhil, Shaker R., Navarro, Alejandro, Rodríguez-Cid, Jerónimo, Schenker, Michael, Lee, Jong-Seok, Gutierrez, Vanesa, Percent, Ivor, Morgensztern, Daniel, Barrios, Carlos H., Greillier, Laurent, Baka, Sofia, Patel, Miten, Lin, Wen Hong, Selvaggi, Giovanni, Baudelet, Christine, Baden, Jonathan, Pandya, Dimple, Doshi, Parul, Kim, Hye Ryun
Publicado 2021

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

por Govindan, Ramaswamy, Aggarwal, Charu, Antonia, Scott J, Davies, Marianne, Dubinett, Steven M, Ferris, Andrea, Forde, Patrick M, Garon, Edward B, Goldberg, Sarah B, Hassan, Raffit, Hellmann, Matthew D, Hirsch, Fred R, Johnson, Melissa L, Malik, Shakun, Morgensztern, Daniel, Neal, Joel W, Patel, Jyoti D, Rimm, David L, Sagorsky, Sarah, Schwartz, Lawrence H, Sepesi, Boris, Herbst, Roy S
Publicado 2022

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

por Wagner, Alex H., Devarakonda, Siddhartha, Skidmore, Zachary L., Krysiak, Kilannin, Ramu, Avinash, Trani, Lee, Kunisaki, Jason, Masood, Ashiq, Waqar, Saiama N., Spies, Nicholas C., Morgensztern, Daniel, Waligorski, Jason, Ponce, Jennifer, Fulton, Robert S., Maggi, Leonard B., Weber, Jason D., Watson, Mark A., O’Conor, Christopher J., Ritter, Jon H., Olsen, Rachelle R., Cheng, Haixia, Mukhopadhyay, Anandaroop, Can, Ismail, Cessna, Melissa H., Oliver, Trudy G., Mardis, Elaine R., Wilson, Richard K., Griffith, Malachi, Griffith, Obi L., Govindan, Ramaswamy
Publicado 2018